Systemic Therapy for Mutation-Driven NSCLC

Lova Sun; Melina E Marmarelis; Corey J Langer

doi:10.1016/j.semradonc.2020.11.011

Systemic Therapy for Mutation-Driven NSCLC

Semin Radiat Oncol. 2021 Apr;31(2):140-148. doi: 10.1016/j.semradonc.2020.11.011.

Authors

Lova Sun¹, Melina E Marmarelis², Corey J Langer²

Affiliations

¹ Division of Hematology/Oncology, Department of Medicine, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA. Electronic address: [email protected].
² Division of Hematology/Oncology, Department of Medicine, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA.

PMID: 33610271
DOI: 10.1016/j.semradonc.2020.11.011

Abstract

Lung cancer is the leading cause of cancer deaths worldwide, and patients with nonsmall cell lung cancer have traditionally had a poor prognosis. An improved understanding of targetable oncogenic molecular alterations has led to a growing number of effective and first-line therapies in targeted patient populations. This review provides an overview of systemic therapy options available for patients with mutation-driven nonsmall cell lung cancer, as well as a discussion of data regarding safety when combined with radiation therapy.

Publication types

Review

MeSH terms

Carcinoma, Non-Small-Cell Lung* / genetics
Carcinoma, Non-Small-Cell Lung* / radiotherapy
Humans
Lung Neoplasms* / genetics
Lung Neoplasms* / radiotherapy
Molecular Targeted Therapy
Mutation